At AimaLabs, we’re revolutionizing hematology diagnostics through cutting-edge artificial intelligence. Our innovative platform brings unprecedented accuracy and efficiency to peripheral blood cell identification, offering a fast, cost-effective solution that addresses a critical global healthcare gap where 1.5 billion people with anemia and blood cancer remain undiagnosed due to limited access to blood smear analysis.
Our vision combines deep medical expertise with advanced AI technology. Founded by Dr. Vasiliki Vlacha, a distinguished Pediatric Hematologist with 35 years of clinical experience and training at Brown University, AimaLabs bridges the gap between traditional hematology and modern technological innovation. https://www.linkedin.com/in/vasiliki-vlacha-59806a8a/
Our exceptional team unites talent from world-leading institutions. Persefoni Perivolaropoulou, with expertise from the University of Edinburgh and Cambridge, brings advanced engineering insight to our solutions. Daniel Tikhomirov, PhD candidate at Cambridge University’s renowned Biomedical Engineering department, serves as our Biomedical Advisor, bringing expertise in advanced medical imaging and machine learning applications in healthcare. Our technical team includes talented AI engineers from the University of Edinburgh and the University of Glasgow, who are developing state-of-the-art algorithms for blood cell analysis.
https://www.linkedin.com/in/persefoni-perivolaropoulou-519556171/
https://www.linkedin.com/in/daniel-tikhomirov-7142891ba/
Together, we’re developing sophisticated AI algorithms that enhance the accuracy and efficiency of blood cell analysis. Our technology not only streamlines laboratory workflows but also democratizes access to expert-level hematological diagnosis, particularly in regions where specialist expertise is scarce, delivering rapid results at a fraction of traditional costs.
At AimaLabs, we believe in the power of combining medical expertise with technological innovation to create solutions that matter. We’re not just developing technology; we’re working to ensure that no patient goes undiagnosed due to lack of access to proper blood analysis.
AIMA Labs 